• 1
    Bennett JM, Komrokji R, Kouides P. The myelodysplastic syndromes. In: Abeloff MD, Armitage JO, Niederhuber JE, eds. Clinical Oncology. New York, NY: Churchill Livingstone, 2004: 2849-2881.
  • 2
    Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am. 2010; 24: 443-457.
  • 3
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.
  • 4
    Myelodysplastic Syndromes. NCCN Clinical Practice Guidelines in Oncology. V2. Fort Washington, PA: NCCN, 2011.
  • 5
    Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113: 1351-1361.
  • 6
    Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25: 3503-3510.
  • 7
    Larson RA. Therapy-related myeloid neoplasms. Haematologica. 2009; 94: 454-459.
  • 8
    Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004; 45: 1311-1318.
  • 9
    Hugo SE, Bundrick SC, Hanson CA, et al. Independent validation of the MD Anderson Cancer Center Risk Model for myelodysplastic syndromes (MDS), and comparison to the International Prognostic Scoring System (IPSS) and the World Health Organization-Based Prognostic Scoring System (WPSS). ASH Annu Meet Abstr. 2009; 114: 3814.
  • 10
    Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110: 4385-4395.